Abstract 249P
Background
PAEP encodes for pregnancy-associated endometrial alpha-2 globulin; a glycoprotein with a wide spectrum of biological actions. One of which is related to immune system modulation. In this work, we evaluated the prognostic potential of PAEP in ccRCC and its impact on tumor immune microenvironment (TIME).
Methods
The ccRCC cohort of the cancer genome atlas program (TCGA) was accessed to obtain relevant clinicopathological parameters alongside PAEP mRNA expression data. Multivariate Cox logistic regression analysis was applied to evaluate the prognostic independency of PAEP expression in predicting the overall survival (OS). Gene set enrichment analysis (GSEA) algorithm was implemented to discern the molecular mechanisms affected by PAEP upregulation. TIME was assessed by predicting the immune suppressive cells infiltration and T-cell dysfunction using TIMER 2.0 and TIDE, respectively.
Results
The Kaplan-Meier estimate showed that high expression of PAEP is associated with shortened OS (HR: 2.511, 95% CI: 1.864-3.384, P < .0001). Multivariate Cox logistic regression analysis depicts PAEP expression as an independent prognostic variable (HR: 1.849, 95% CI: 1.304-2.621, P = .001). GSEA (H1: Hallmarks of cancer gene sets) identified the following pathways to be involved in the poor prognostic signature of PAEP: epithelial-mesenchymal transition, G2M checkpoint, E2F targets, IL6/JAK/STAT3 signaling, coagulation, complement, KRAS downregulation, and inflammatory response. TIME showed a significant infiltration of several immunosuppressive cellular elements including regulatory T cells (ρ = 0.256, P < .0001), cancer-associated fibroblasts (ρ = 0.194, P < .0001), and myeloid-derived suppressor cells (ρ = 0.194, P < .0001). PAEP was not associated with a significant T-cell dysfunction (continuous z score = −0.787, P = .431).
Conclusions
PAPE is being identified as potential prognostic biomarker in ccRCC that impact TIEM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Final analysis of phase II clinical study evaluating the safety and effectiveness of neoadjuvant S-1 + oxaliplatin combination therapy for older patients with locally advanced gastric cancer
Presenter: Eiji Oki
Session: Poster Display
Resources:
Abstract
184P - Neutropenia as a predictive and prognostic factor in nanoliposomal-irinotecan/fluorouracil/leucovorin therapy for pancreatic cancer: Findings from the NAPOLEON-2 study (NN-2301)
Presenter: Yuki Sonoda
Session: Poster Display
Resources:
Abstract
185P - Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
186P - Efficacy and safety of fruquintinib with nab-paclitaxel in advanced G/GEJ cancer after exposure to immune checkpoint inhibitors: A single-center prospective clinical trial
Presenter: Xiaoting Ma
Session: Poster Display
Resources:
Abstract
187P - Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus transhepatic arterial infusion chemotherapy (HAIC) for resectable multinodular CNLC Ib/IIa hepatocellular carcinoma (Car-Hero)
Presenter: Yongguang Wei
Session: Poster Display
Resources:
Abstract
188P - Impact of metformin, statin, aspirin and insulin on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab
Presenter: Margherita Rimini
Session: Poster Display
Resources:
Abstract
189P - Safety run-in results from LEAP-014: First-line lenvatinib (len) plus pembrolizumab (pembro) and chemotherapy (chemo) for metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Shun Yamamoto
Session: Poster Display
Resources:
Abstract
190P - Perioperative camrelizumab combined with chemotherapy for locally advanced gastric or gastroesophageal junction adenocarcinoma: A single-arm, single-center, phase II clinical trial
Presenter: Jiaxing He
Session: Poster Display
Resources:
Abstract
191P - Predictive value of CXCR6 expression in gastric cancer survival and immune modulation
Presenter: Song-Hee han
Session: Poster Display
Resources:
Abstract
192P - Antiangiogenesis-related adverse events (ARAE) to predict efficacy in patients with advanced gastric cancer (AGC) treated with apatinib + chemotherapy: Results from two prospective studies
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract